Editas Medicine Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Editas Medicinehan disminuido a un ritmo medio anual de -15.5%, mientras que en la industria Biotechs los ingresos han sido de growing a 17.4% anuales. Los ingresos han sido declining a una tasa media anual de 4.1%.

Información clave

-14.0%

Tasa de crecimiento de los beneficios

-4.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	0.4%
Rentabilidad financiera	-43.9%
Margen neto	-196.1%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Apr 23

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Mar 09

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

Feb 28

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Dec 15

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

May 10

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Jan 19

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Oct 18

Editas Medicine started at neutral at BofA due to competition in gene editing programs

Sep 29

Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

Feb 25

Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price Recently

Dec 28

Editas - The Introvert Crispr Biotech Too Shy To Flex Its Muscles

Dec 15

Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Nov 17

Editas: Data Was Eagerly Anticipated But Failed To Impress

Nov 03

Is Editas Medicine (NASDAQ:EDIT) Using Too Much Debt?

Sep 07

Editas: Gene Therapy Specialist Leading The Way In Eye Disease

Aug 27

Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation

Aug 12

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Editas Medicine. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:EDIT Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	78	-153	70	0
30 Sep 23	25	-195	73	0
30 Jun 23	19	-206	74	0
31 Mar 23	23	-219	74	1
31 Dec 22	20	-220	71	0
30 Sep 22	26	-201	69	0
30 Jun 22	32	-184	69	0
31 Mar 22	26	-186	74	34
31 Dec 21	26	-193	76	0
30 Sep 21	24	-214	75	0
30 Jun 21	81	-167	79	0
31 Mar 21	92	-135	71	0
31 Dec 20	91	-116	68	0
30 Sep 20	92	-91	69	0
30 Jun 20	33	-132	65	0
31 Mar 20	24	-142	65	0
31 Dec 19	21	-134	65	0
30 Sep 19	14	-121	61	0
30 Jun 19	25	-103	58	0
31 Mar 19	30	-108	58	0
31 Dec 18	32	-110	55	0
30 Sep 18	29	-121	56	0
30 Jun 18	21	-132	55	0
31 Mar 18	17	-120	52	0
31 Dec 17	14	-120	51	0
30 Sep 17	11	-124	50	0
30 Jun 17	6	-118	49	0
31 Mar 17	6	-111	49	0
31 Dec 16	6	-97	46	0
30 Sep 16	6	-71	41	0
30 Jun 16	6	-57	33	0
31 Mar 16	2	-86	25	0
31 Dec 15	2	-73	18	0
30 Sep 15	1	-66	14	0
30 Jun 15	0	-62	11	0
31 Mar 15	0	-17	9	0
31 Dec 14	0	-14	8	0

Ingresos de calidad: EDIT actualmente no es rentable.

Margen de beneficios creciente: EDIT actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: EDIT no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 15.5% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de EDIT en el último año con su media de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: EDIT no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Biotechs (-42.7%).

Rentabilidad financiera

Alta ROE: EDIT tiene un Rendimiento de los fondos propios negativo (-54.12%), ya que actualmente no es rentable.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Editas Medicine Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%

Editas Medicine, Inc., Annual General Meeting, May 30, 2024

President recently sold US$733k worth of stock

Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement

President notifies of intention to sell stock

Consensus revenue estimates increase by 49%, EPS downgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch

New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)

Consensus revenue estimates increase by 25%

Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology (ASH) Annual Meeting And In A Company-Sponsored Webinar

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored Webinar

Editas Medicine, Inc. Announces Bruce E. Eaton Will Step Down as Chief Technology Officer and Chief Business Officer, Effective January 2, 2024

Editas Medicine, Inc. Appoints Caren Deardorf as Chief Commercial and Strategy Officer

Consensus revenue estimates decrease by 13%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Medicine, Inc. Announces Appointment of Linda C. Burkly as Executive Vice President and Chief Scientific Officer

New minor risk - Shareholder dilution

Editas Medicine, Inc. Announces Positive Initial Edit-301 Safety and Efficacy Data from the First Four Patients Treated in the Phase I/II Clinical Trial

Editas Medicine, Inc. Announces Management Changes

Editas Medicine, Inc. to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

Consensus revenue estimates increase by 14%

Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

CFO, Principal Accounting Officer notifies of intention to sell stock

Price target decreased by 8.6% to US$13.06

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CFO, Principal Accounting Officer notifies of intention to sell stock

Shoreline Biosciences, Inc. entered into a definitive agreement to acquire Editas Medicine iNK cell franchise, EDIT-202 and certain related manufacturing technology from Editas Medicine, Inc.

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?

Price target decreased to US$14.19

Editas Medicine, Inc. Announces Step Down of Mark S. Shearman as Executive Vice President and Chief Scientific Officer, Effective March 31, 2023

Price target decreased to US$16.73

Editas Medicine, Inc. Announces Positive, Initial Clinical Data from First Two Patients with Sickle Cell Disease Treated with EDIT-301 in Phase 1/2 RUBY Trial

Editas Medicine, Inc. Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

Price target decreased to US$25.87

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Editas Reportedly in Talks to Sell Preclinical Oncology Assets

Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the European Society of Gene and Cell Therapy Annual Meeting

Editas Medicine started at neutral at BofA due to competition in gene editing programs

We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely

Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Editas Medicine Q2 2022 Earnings Preview

Editas Medicine, Inc. Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

Editas Medicine Appoints Baisong Mei, as Chief Medical Officer

Baisong Mei joins Editas Medicine as Chief Medical Officer

Executive VP & Chief Scientific Officer recently sold US$52k worth of stock

Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?

Editas: Tackling Rare Eye Disease With Use Of Crispr Technology

Consensus revenue estimates fall by 12%

Price target decreased to US$31.21

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Editas Medicine, Inc. Presents Preclinical Data on Edit-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa At the Association for Research in Vison and Ophthalmology Conference

Editas Medicine, Inc. Announces Executive Changes, Effective June 1, 2022

Editas Medicine, Inc. Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

Executive VP & Chief Business Officer notifies of intention to sell stock

Editas: The Unforeseen Detrimental Effect Of Patent Win

Editas: CRISPR Gene Editing Biotech With Promising Future

Editas Medicine, Inc. Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$37.23

Consensus revenue estimates increase by 15%

Desglose de ingresos y gastos
Beta